Ursodeoxycholic Acid Market Report Overview
-
Request a Free Sample to learn more about this report
The global ursodeoxycholic acid market size was USD 840.03 million in 2021 and is projected to touch USD 1999.21 million by 2031 with a CAGR of 9.06% during the forecast period.
Ursodeoxycholic acid is primarily used as treatment for cholestatic liver diseases. This is an acid which occurs naturally in the form of bile acid. This medication is an effective agent in dissolving gall stones and treating primary biliary cirrhosis. It is used in large quantities in the medical industry to treat liver diseases.
UDCA therapy is found out to be very effective in treating medical conditions like cystic fibrosis, and, primary biliary cirrhosis. Hence, the number of people opting for this treatment has significantly increased. These factors have helped in the growth of the ursodeoxycholic acid market share.
COVID-19 impact: Lack of Treatment for Other Diseases During Pandemic Decreased Market Growth
The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden spike in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.
The outbreak of pandemic of COVID-19 resulted in the downfall of economy of various countries globally. People also suffered from medical conditions. There had been a spike in death rates during COVID, due to the spreading infection. Hospitals were completely accommodated with patients.
Some people could not even find hospitals to get themselves treated. With the rapidly spreading infection of coronavirus, greater focus was given on treating patients who suffered from COVID. People with other medical conditions found it difficult to get access to any form of treatment. Lack of treatment during pandemic, resulted in the downfall of ursodeoxycholic acid market growth.
LATEST TRENDS
"Improvement of Liver Health After Administration of UDCA Therapy to Increase Market Growth"
UDCA therapy to given to patients who are suffering from liver related problems. Ursodeoxcholic acid can be given either in the form of a tablet or in the form of a liquid. Along with helping in getting rid of gallstones, this acid is highly effective in preventing the formation of cystic fibrosis related liver infections and disorders.
Using this medication is beneficial to patients as it can also delay the formation of gastroesophageal varices. Cirrhosis is another deadly liver disease that can be witnessed in patients. This can also be treated effectively with the administration of UDCA therapy. UDCA therapy is gaining popularity in the medical industry as it provides solution to several liver related problems. This is identified as the latest trend in the market.
Ursodeoxycholic Acid Market Segmentation
-
Request a Free Sample to learn more about this report
- By Type:
The market can be divided on the basis of type into the following segments:
Synthetic ursodeoxycholic acid, and, extraction ursodeoxycholic acid. The synthetic ursodeoxycholic acid segment is anticipated to dominate the market during the forecast period.
- By Application:
Classification based on application into the following segment:
Pharmacy, and, health products. The pharmacy segment is predicted to dominate the market during the research period.
DRIVING FACTORS
"Rising Cases of Cystic Fibrosis as Well as Gall Stones to Accelerate Market Growth"
Gall stones and cystic fibrosis, are some of the common cases that can be identified among people. Gall stones are formed when bile juices contain high level of cholesterol. Bile juice of a normal person will have certain chemicals that can dissolve the cholesterol which is present in our body.
However, if the amount of cholesterol which is excreted by our liver is greater than the amount of cholesterol that the liver can dissolve it can lead to formation of gall stones. Formation of gall stones in our body can be painful. Also, this condition is harmful, as the retention of gall stones within our body can obstruct the flow of bile juice. Therefore, ursodeoxycholic acid is prescribed to patients with this condition. Increasing prevalence of liver disorders is driving the development of market.
"Use of Ursodeoxcholic Acid for Treating Patients Who Cannot Undergo Gallbladder Surgery to Propel Market Growth "
Due to certain health conditions people suffering from, gall stones cannot undergo a gall bladder surgery. Without a surgery it would be difficult to remove such stones from the body, which could further lead up to other complications. Such patients are given UDCA therapy.
This acid is highly versatile and is suitable for treating various forms of liver diseases. Bile duct paucity syndromes, liver allograft rejection, biliary atresia, and non-alcoholic steatohepatitis are some other liver disorders that can be treated with this acid. All of these factors are propelling the market growth.
RESTRAINING FACTOR
"Side Effects of Using Ursodeoxycholic Acid to Bring Down Market Growth"
In spite of being one of the best medications for most of the liver disorders, using of this acid continually for a very long period of time can still cause some side effects to human body. This factor can downgrade the market growth.
Ursodeoxycholic acid can cause certain problems which involve bloody or cloudy urine, faster heartbeat, severe nausea, stomach pain, skin rashes, body itchiness, frequent urge to urinate, severe bladder pain, and difficulty in urination. These problems can decrease the consumer base for the market.
Ursodeoxycholic Acid Market Regional Insights
-
Request a Free Sample to learn more about this report
"North America to Dominate Market in Upcoming Years"
The largest market share is held by North America. It accounts for more than one-fourth of the market. The main reason for development of market in this region in the increasing prevalence of liver disorders among people especially the elderly population.
UDCA therapy is gradually gaining popularity in this region, as it provides a quick and less complicated solution for severe liver diseases. Sedentary lifestyle of people is resulting in higher levels of cholesterol in the body. This can in turn cause gall stones. Concentration of a greater number of manufacturers in this region is another factor propelling the market growth.
Key Industry Players
"Leading Players adopt Acquisition Strategies to Stay Competitive "
Several players in the market are using acquisition strategies to build their business portfolio and strengthen their market position. In addition, partnerships and collaborations are among the common strategies adopted by companies. Key market players are making R&D investments to bring advanced technologies and solutions to the market. A lot of developments have been witnessed in the market.
List of Market Players Profiled
- Erregierre (Italy)
- Daewoong chemical (Korea)
- Mitsubishi (Japan) (
- Biotavia Labs (India)
- Pharma Zell GmbH (Germany)
- Abil Chem pharma (India)
- ICE (U.S.)
- Grindeks (Latvia)
- Suzhou Tianlu (China)
- Dipharma Francis (Italy)
Report Coverage
The report provides an insight into the industry from both the demand and supply sides. Further, it also gives information on the impact of COVID-19 on the market, the driving and the restraining factors along with the regional insights. Market dynamic forces during the forecast period have also been discussed for the better understanding of the market situations. Information regarding key market players is also provided to get an outlook about the competition in the market.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 840.03 Million in 2021 |
Market Size Value By |
US$ 1999.21 Million by 2031 |
Growth Rate |
CAGR of 9.06% from 2021 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is ursodeoxycholic acid market expected to touch by 2031?
The ursodeoxycholic acid market is projected and estimated to touch USD 1999.21 million by 2031.
-
What CAGR is the ursodeoxycholic acid market expected to exhibit by 2031?
The ursodeoxycholic acid market is expected to exhibit a CAGR of 9.06% by 2031.
-
Which are the driving factors of the ursodeoxycholic acid market?
UDCA therapy is found out to be very effective in treating medical conditions like cystic fibrosis, and, primary biliary cirrhosis. Hence, the number of people opting for this treatment has significantly increased.
-
Which are the top companies operating in the ursodeoxycholic acid market?
Erregierre, Daewoong chemical, Mitsubishi, Zhangshanbelling, Biotavia Labs are the top companies operating in the ursodeoxycholic acid market.